SYF2 ASO

SYF2 ASO is an investigational antisense oligonucleotide (ASO) therapy designed to target and suppress the expression of the spliceosome-associated factor SYF2. The drug aims to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two fatal neurodegenerative diseases characterized by TDP-43 proteinopathy. By reducing SYF2 levels, this therapy alleviates TDP-43 aggregation and mislocalization, improves TDP-43 activity, and rescues neuron survival in both genetic and sporadic forms of ALS. Preclinical studies have shown that suppression of Syf2 ameliorates neurodegeneration, neuromuscular junction loss, and motor dysfunction in animal models. The approach leverages proprietary ASO design software to optimize candidate sequences for efficacy, stability, manufacturability, reduced immunogenicity, and minimal off-target effects[1][3][5].

Other names

SYF2 antisense oligonucleotideSYF-2 antisense oligonucleotideSYF 2 antisense oligonucleotide